CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 6.6: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.82BCNY720.18M · vs all stocks (USD)
Revenue (TTM)
533.88MCNY79.72M · vs all stocks (USD)
Profit Margin
-24.78%Beta
0.1630xvs all stocks
52-Week Change
26.04%vs all stocks
Market Capitalization
4.82BCNY720.18M · vs all stocks (USD)
Enterprise Value
4.18BCNY623.94M · vs all stocks (USD)
Price to Sales (TTM)
8.92xPrice to Book (MRQ)
2.90xEnterprise to Revenue
7.83xEnterprise to EBITDA
-117.75xGross Margin
9.35%Profit Margin
-24.78%Operating Margin
-15.74%Return on Assets (TTM)
-2.93%Return on Equity (TTM)
-8.32%Revenue (TTM)
533.88MCNY79.72M · vs all stocks (USD)
Revenue per Share (TTM)
0.3050CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-6.70%Gross Profit (TTM)
61.00MCNY9.11M · vs all stocks (USD)
EBITDA (TTM)
6.99MCNY1.04M · vs all stocks (USD)
Net Income (TTM)
-132.30MCNY-19.76M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
6.42%Operating Cash Flow (TTM)
25.05MCNY3.74M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
77.60MCNY11.59M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
-5.26MCNYFY2025 · Dec 31, 2025Revenue
577.34MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
473.84MCNYFY2025 · Dec 31, 2025Gross Profit
103.50MCNYFY2025 · Dec 31, 2025Operating Income
-62.32MCNY-9.31M · vs all stocks (USD)
Pre-tax Income
-121.46MCNYFY2025 · Dec 31, 2025Income Tax Expense
-8.51MCNYFY2025 · Dec 31, 2025Net Income
-112.94MCNYFY2025 · Dec 31, 2025EBIT
-120.79MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
6.99MCNYFY2025 · Dec 31, 2025Research & Development
12.16MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
57.65MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.77MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.58MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
664.12KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0600CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.90BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.90BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-112.94MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.25MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
7.24MCNYFY2025 · Dec 31, 2025Free Cash Flow
-17.52MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
338.61MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-112.94MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.90MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
24.13MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
94.16MCNYFY2025 · Dec 31, 2025Capital Expenditures
-24.76MCNYFY2025 · Dec 31, 2025Purchase of Investments
-102.90MCNYFY2025 · Dec 31, 2025Sale of Investments
88.40MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-39.26MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
8.22MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-32.96KCNYFY2025 · Dec 31, 2025Other Financing Charges
-2.92MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
5.27MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.99BSharesUpdated Sep 21, 2026Float Shares
847.25MSharesUpdated Sep 21, 2026% Held by Insiders
54.68%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
440.82MCNY65.83M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2280CNYUpdated Sep 21, 2026Total Debt (MRQ)
29.17MCNY4.36M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0186xCurrent Ratio (MRQ)
3.17xBook Value per Share (MRQ)
0.8250CNYUpdated Sep 21, 2026Total Assets
1.97BCNY294.82M · vs all stocks (USD)
Total Current Assets
1.12BCNYFY2025 · Dec 31, 2025Total Liabilities
343.56MCNYFY2025 · Dec 31, 2025Total Non-current Assets
859.02MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
26.33MCNYFY2025 · Dec 31, 2025Total Current Liabilities
317.23MCNYFY2025 · Dec 31, 2025Cash
388.42MCNYFY2025 · Dec 31, 2025Cash Equivalents
707.35KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
389.13MCNYFY2025 · Dec 31, 2025Accounts Receivable
85.13MCNYFY2025 · Dec 31, 2025Inventory
191.29MCNYFY2025 · Dec 31, 2025Accounts Payable
68.23MCNYFY2025 · Dec 31, 2025Short-term Debt
11.48MCNYFY2025 · Dec 31, 2025Other Current Liabilities
3.28MCNYFY2025 · Dec 31, 2025Long-term Debt
10.64MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.99BCNYFY2025 · Dec 31, 2025Retained Earnings
-3.38BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.63BCNY243.52M · vs all stocks (USD)
Treasury Stock
90.00MCNYFY2025 · Dec 31, 202552-Week Low
1.76CNYUpdated Sep 21, 202652-Week High
3.27CNYUpdated Sep 21, 202652-Week Change
26.04%vs all stocks
Beta
0.1630xvs all stocks
50-Day MA
2.25CNYUpdated Sep 21, 2026200-Day MA
2.56CNYUpdated Sep 21, 2026Avg 10-Day Volume
13.56MSharesUpdated Sep 21, 2026Avg 30-Day Volume
8.90MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-0.0700CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.6: safe zoneNotable
Altman Z-Score: 6.60
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Beilu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sanyou Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Knight Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yabao Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wave Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Center Laboratories, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Lifotronic Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Konruns Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cytek Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule